BridgeMD
New treatment option for Diffuse Large B-Cell Lymphoma
Official title A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
ClinicalTrials.gov ID: NCT05512390
What this study is testing
What is ABBV-319?
ABBV-319 is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for diffuse large b-cell lymphoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- For dose escalation (Part 1) only: Participants with documented diagnosis of B-cell malignancies including those with histology based on criteria...
- For the relapsed or refractory diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and Chronic lymphocytic leukemia (CLL) dose expansion...
- Laboratory values meeting the criteria noted in the protocol.
- For participants previously treated with a CD19-targeting therapy (eg, CD19 monoclonal antibody) a core or excision tumor biopsy subsequent to the...
- Participant must have measurable disease, as defined by the 2014 Lugano Classification.
You likely can't join if
- Known active central nervous system (CNS) disease, or primary CNS lymphoma.
- Known active infection or clinically significant uncontrolled conditions as per the protocol.
- Eastern Cooperative Oncology Group (ECOG) performance status \>= 2.
The study team makes the final eligibility decision.
Where it's taking place
- Tucson, Arizona, United States
- Miami, Florida, United States
- Minneapolis, Minnesota, United States
- Omaha, Nebraska, United States
- New York, New York, United States
- Charlotte, North Carolina, United States
- Dallas, Texas, United States
- San Antonio, Texas, United States
- Concord, New South Wales, Australia
- Fitzroy Melbourne, Victoria, Australia
- Nedlands, Western Australia, Australia
- Edmonton, Alberta, Canada
- Toronto, Ontario, Canada
- Ramat Gan, Tel Aviv, Israel
- Jerusalem, Israel
- Seoul, Seoul Teugbyeolsi, South Korea
- Santander, Cantabria, Spain
- Madrid, Spain
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tucson, Arizona, United States; Miami, Florida, United States; Minneapolis, Minnesota, United States; Omaha, Nebraska, United States; New York, New York, United States; Charlotte, North Carolina, United States and 12 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.